Uptick in Cabenuva Usage Among Medicare Recipients

A recent study from the Harvard T.H. Chan School of Public Health reveals a steady uptick in the use of Cabenuva, a long-acting injectable treatment for HIV, among Medicare recipients.

Medicare, commonly known for serving senior citizens, also extends its services to individuals with long-term disabilities, including many who qualify for dual enrollment in Medicare and Medicaid due to conditions like HIV. Although Cabenuva was approved in 2021, its use in this demographic has been rising slowly. In 2021, only 0.4% of Medicare-enrolled individuals with HIV utilized the treatment, which increased to 1.9% in 2022 and further to 3.0% in 2023. Despite this encouraging trend, usage remains limited, suggesting a need for broader accessibility.

Financial Barriers and Demographic Disparities

Financial barriers significantly impact the accessibility of Cabenuva among Medicare recipients, underscoring the economic challenges in expanding patient access to innovative treatments. The study highlights that certain groups—such as older adults, Native Americans, and those living in rural areas or the Southern United States—experience notably fewer prescriptions for Cabenuva. This disparity points to a pressing need for policy adjustments to improve affordability and access to essential healthcare services.

Reasons for Limited Access

The limited uptake of Cabenuva underscores several challenges that must be addressed to improve access to long-acting HIV treatments among Medicare beneficiaries:

• Financial Barriers: High costs associated with Cabenuva remain a significant hurdle.
• Geographical Disparities: Individuals in rural or Southern regions face fewer opportunities to access this treatment.
• Demographic Differences: Older adults and certain minority groups have lower usage rates, revealing a need for targeted outreach.

As the insurance industry navigates these evolving dynamics, there is a critical need for strategic approaches to balance cost management with broad treatment accessibility. Industry professionals, particularly insurance agents and claims professionals, must remain attentive to these trends, as they have profound implications for coverage strategies and regulatory considerations.